Posted by Michael Wonder on 07 Nov 2023
Health Canada approves Doptelet (avatrombopag) for two indications in thrombocytopenia
6 November 2023 - Doptelet is the only oral thrombopoietin receptor agonist without food-type restrictions or significant hepatotoxicity.
Sobi North America today announced that Health Canada has approved Doptelet (avatrombopag), an oral thrombopoietin receptor agonist, for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment and for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
